Lupin receives tentative approval from USFDA for Canagliflozin Tablets
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
This product will be manufactured at Lupin’s Pithampur facility in India
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
She joins Enveda from Gilead Sciences
Subscribe To Our Newsletter & Stay Updated